Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP)

Since 2014, programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) checkpoint inhibitors have been approved by various regulatory agencies for the treatment of multiple cancers including melanoma, lung cancer, urothelial carcinoma, renal cell carcinoma, head and neck cancer, c...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Appl Immunohistochem Mol Morphol
Main Authors: Cheung, Carol C., Barnes, Penny, Bigras, Gilbert, Boerner, Scott, Butany, Jagdish, Calabrese, Fiorella, Couture, Christian, Deschenes, Jean, El-Zimaity, Hala, Fischer, Gabor, Fiset, Pierre O., Garratt, John, Geldenhuys, Laurette, Gilks, C. Blake, Ilie, Marius, Ionescu, Diana, Lim, Hyun J., Manning, Lisa, Mansoor, Adnan, Riddell, Robert, Ross, Catherine, Roy-Chowdhuri, Sinchita, Spatz, Alan, Swanson, Paul E., Tron, Victor A., Tsao, Ming-Sound, Wang, Hangjun, Xu, Zhaolin, Torlakovic, Emina E.
Formato: Artigo
Idioma:Inglês
Publicado em: Lippincott Williams & Wilkins 2019
Assuntos:
Hot Topic
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6887625/
https://ncbi.nlm.nih.gov/pubmed/31584451
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/PAI.0000000000000800
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados